KR20140127639A - A composition comprising Astragaloside IV for preventing hair loss or promoting hair growth - Google Patents

Abstract

The present invention relates to a pharmaceutical composition, a functional health food, and a cosmetic composition comprising astragaloside IV for preventing hair loss or promoting hair growth. The astragaloside IV of the present invention inhibits cell death in hair follicles and promotes the growth of hair. The composition can be usefully applied in preventing or treating hair loss by having excellent effects of preventing hair loss and promoting hair growth.

Description

[0001] The present invention relates to a composition for preventing hair loss or promoting hair growth comprising Astragaloside IV,

The present invention relates to a pharmaceutical composition, a health functional food and a cosmetic composition for prevention or treatment of alopecia containing Astragaloside IV.

Hair loss refers to the state of hair where hair normally should be present, and genetic factors are known to be the main cause. Recently, with the increase of social stress, the hair loss population is gradually increasing due to westernized eating habits such as environmental pollution and instant food, frequent perm and dyeing, and incorrect scalp care.

The hair is maintained by repeating hair growth and hair loss around the cycles of Anagen, Catagen and Telogen. Specifically, there are anagen which grows hair, catagen which is the period of termination of growth and reduction of the size of the moles, talag, which is the period when the papilla stops its activity and keeps its hair on the scalp, Or a generator that generates new hair to depilate old hair. Hair growth is 3 ~ 5 years for males and 4 ~ 6 years for females. After that, 30 ~ 45 days of degeneration and 3 ~ 4 months of rest period are natural hair loss. And at the end of the pause, a generator starts to generate new hair. Hair loss is a normal phenomenon, but normal people are growing hair. Many people with Alopecia usually have a lot of hair in a resting state, causing visible hair loss.

The formation of hair follicles is characterized by the formation of a placode by the action of β-catenin (Laura C. 2003), the hair follicle is completed from the formed origin plate and the hair follicle inside the hair follicle papilla cell) to produce hair. The period of hair growth is called the growth period. The hair that is first generated enters the resting phase through the growing phase, which is hairless through the regenerator and cycles back into the growing phase.

More specific hair cycle is as follows.

The Anagen Stage (2-7 years) is the period of hair growth. The growing phase consists of a hair growth phase where the hair tries to exit from the parent hair to the blanket, and a stage where the hard keratin is made inside the hair follicle. The life span of the growing season is 2 ~ 7 years and it occupies 89 ~ 90% of total hair (100 ~ 150 thousand). During the growing stage, the hair grows about 1 ~ 1.5cm per month on average.

The Catagen Stage (2 to 3 weeks) grows slowly at the end of the growing season, while maintaining the shape of the hair and slowing the metabolic process. At this stage, keratin is not produced. The life expectancy of the deformer is 2 to 3 weeks, which accounts for 1% of the total hair. The femur contracts and divides into a dummy, surrounded by hair follicles and climbs upwards. At this time, cell division is stopped.

In the Talogen Stage (3 months), the dermal papilla shrinks and the hair follicles gradually shrink, and the hair follicles are pushed upwards and fall off. The duration of hair loss is 3 ~ 4 months until the next stage of growth, and 4 ~ 14% of total hair (30 ~ 40% after delivery).

The characteristic of people who exhibit alopecia is in the miniaturization of hair. As the hair loss progresses, the period of growth is shortened and the hair becomes smaller and smaller. Therefore, for the treatment of hair loss, it is important to make the resting hair follicles grow into a state of growth, and to shorten the growth period.

Alopecia can be classified into male pattern alopecia and female pattern hair loss, and other alopecia are alopecia areata and alopecia due to other causes.

Male alopecia are caused by testosterone, a testosterone that turns into a more powerful hormone, dihydrotestosterone (DHT), by an enzyme called 5-alpha-reductase. Hormone acts on the hair follicle to induce the hair follicle from the growing stage to the regenerator stage to cause hair loss. Therefore, in order to treat alopecia caused by these causes, a method of suppressing the production of DHT by 5 alpha-reductase is mainly used.

Female alopecia are caused mainly by a decrease in the amount of estrogen after menopause. Unlike the shape of male alopecia, female hair loss does not fall into the front part of the head, and only the hair in the middle part is mainly hair loss. Female alopecia affects less than men in the association with 5 alpha - reductase. Therefore, drugs that inhibit 5 alpha-reductase inhibition are not effective for postmenopausal women with alopecia. Accordingly, minoxidil or estrogen is mainly used as a therapeutic agent for such alopecia. Alopecia areata is caused by autoimmune diseases, mental stress, genetic predisposition. It is characterized by the appearance of round or oval hair loss, and the appearance of tofu rings or hairy walls. These alopecia areata are fundamentally different from those of androgenetic alopecia, and different methods are used to treat the adrenocorticotropic agent, minoxidil is applied to the affected part, or artificially induced to the affected part.

With respect to such various and complicated hair loss causes, known hair loss prevention products to date have been marketed as products in the market as effective ingredients for promoting blood circulation, inhibiting male hormone function, and strengthening hair follicle function. There are no clear effects yet and there are side effects.

Recently, it has been known that the hair growth promoting effect is caused by side effects among patients who have been developed and used for promotion of blood circulation at first, and then they are used as a hair growth promoting raw material in the US Food and Drug Administration (FDA) 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidine of U.S. Patent No. 3,382,247, which is approved as a hair growth inhibitor, and finasteride ).

However, minoxidil has been reported to have a sticky feel and side effects that cause irritation to the skin. In the case of pinasteride, it is currently used as a preparation for oral administration. However, adverse effects such as sexual dysfunction have been reported depending on its consumption, There is a side effect that hair loss should be treated consistently.

Accordingly, the inventors of the present invention confirmed that Astragaloside IV inhibits hair loss and promotes hair growth while continuing research on new substances that can replace conventional hair growth agents, and completed the present invention.

U.S. Patent No. 3,382,247 U.S. Patent No. 5,215,894

It is an object of the present invention to provide a pharmaceutical composition for preventing hair loss or promoting hair growth comprising Astragaloside IV as an active ingredient.

It is also an object of the present invention to provide a health functional food for preventing hair loss or promoting hair growth comprising Astragaloside IV as an active ingredient.

It is also an object of the present invention to provide a cosmetic composition for preventing hair loss or promoting hair growth comprising Astragaloside IV as an active ingredient.

The present invention provides a pharmaceutical composition for preventing hair loss or promoting hair growth comprising Astragaloside IV as an active ingredient.

The present invention also provides a pharmaceutical composition for preventing hair loss or promoting hair growth, wherein the astragaloside IV promotes hair growth.

The present invention also provides a pharmaceutical composition for preventing hair loss or promoting hair growth, wherein the astragaloside IV inhibits cell death in hair follicles.

The present invention also relates to a pharmaceutical composition for preventing hair loss or promoting hair growth, wherein said astragaloside IV reduces the production of at least one cytokine selected from the group consisting of TNF-? IL-1? IL-4 and IL? to provide.

The present invention also provides a pharmaceutical composition for preventing hair loss and promoting hair growth, the composition having a formulation selected from the group consisting of a solution for external use, cream, ointment, paste, aerosol, gel and lotion.

The present invention also provides a health functional food for preventing hair loss or promoting hair growth comprising Astragaloside IV as an active ingredient.

The present invention also provides a cosmetic composition for preventing hair loss or promoting hair growth comprising Astragaloside IV as an active ingredient.

Astragaloside IV of the present invention is effective in preventing hair loss and promoting hair growth by inhibiting cell death in hair follicles and promoting hair growth.

FIG. 1 is a diagram for confirming the hair growth effect according to the treatment of Astragaloside IV in the back of a mouse.
FIG. 2 shows recovery of damaged hair and growth of new hair following treatment with Astragaloside IV using H & E staining method.
FIGS. 3 and 4 are graphs showing the results of confirming the effect of astragaloside IV treatment on the cytotoxicity of hair follicles as TUNEL assay and caspase-3 positive cells. FIG.
FIG. 5 is a graph showing reduction of expression of caspase-3, -8 and -9, and decrease of Bax and p53 by treatment with astragaloside IV.
FIG. 6 and FIG. 7 are graphs showing the decrease of expression of NF-.kappa.B, phosphorylated p-IκB-.alpha. And expression of i-Nos and Cox-2 by treatment with Astragaloside IV.
FIG. 8 is a graph showing the inhibitory effect of ERK, SAPK / JNK and p38 phosphorylation by astragaloside IV treatment.
Fig. 9 shows inhibition of c-fos and c-Jun by astragaloside IV treatment.

The present invention relates to a pharmaceutical composition for preventing hair loss or accelerating hair growth comprising Astragaloside IV as an active ingredient.

Astragaloside IV of the present invention is effective as a pharmaceutical composition for preventing hair loss or promoting hair growth because it inhibits apoptosis in hair follicles and promotes hair growth, thereby preventing hair loss and promoting hair growth have.

Astragaloside IV may be purified from natural materials containing astragaloside IV as a saponin-based material, or may be obtained by purchasing purified Astragaloside IV.

The Astragaloside IV may exhibit an anti-inflammatory action that suppresses inflammation. When applied to a hair follicle of the deteriorator, the astragaloside IV suppresses apoptosis factor in the hair follicle, suppresses cell death, promotes hair growth, The state can be shifted to the follicular phase of the growing period.

The Astragaloside IV can reduce the production of one or more cytokines selected from the group consisting of TNF- [alpha], IL-1 [beta], IL-4 and IL6.

The composition of the present invention may be administered in various formulations, oral and parenteral, at the time of actual clinical administration. The composition may preferably have one type of formulation selected from external liquid preparations, creams, ointments, pastes, aerosols, gels and lotions.

When the composition of the present invention is formulated into pharmaceutical preparations, it can be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, and surfactants which are usually used.

Solid formulations for oral administration include tablets, pills, powders, granules and capsules, which may be prepared by mixing the pharmaceutical composition of the present invention with at least one excipient such as starch, calcium carbonate, sucrose, lactose And gelatin. In addition to simple excipients, lubricants such as magnesium, stearide, and talc may also be used.

Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups. Various excipients such as wetting agents, sweeteners, fragrances and preservatives may be included in addition to water and liquid paraffin, which are commonly used simple diluents. have.

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Witepsol, macrogol, tween 61, cacao paper, laurin, glycerol, gelatin and the like may be used as a base for suppositories. The pharmaceutical composition of the present invention can be administered by parenteral administration by subcutaneous injection, intravenous injection, or intramuscular injection.

The dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the administration route and the period, and can be appropriately selected by those skilled in the art. However, for the desired effect, the astragaloside IV of the present invention is preferably administered at a dose of 0.1 to 1000 mg / kg per day. The administration may be carried out once a day or divided into several doses. However, the scope of the present invention is not limited to these dosages.

The composition of the present invention can be used alone or in combination with methods using hormone therapy, chemotherapy, and biological response modifiers for hair loss prevention or hair growth promotion.

The present invention also provides a health functional food for preventing hair loss or promoting hair growth comprising Astragaloside IV as an active ingredient.

The health functional food of the present invention may be added astragaloside IV intact or may be used together with other food or food ingredients, and may be suitably used according to conventional methods. The content of the active ingredient may be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, astragaloside IV of the present invention can be added in the range of 0.01 to 15% by weight based on the total weight of the food during the manufacture of food or beverage.

There is no particular limitation on the kind of the food. Examples of foods to which astragaloside IV of the present invention can be added include beverages, gums, vitamin complexes, and drinks, all of which include health functional foods in the conventional sense.

The health functional food of the present invention may be a health functional beverage, and the beverage may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the natural carbohydrate include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Flavoring agents (saccharin, aspartame, etc.) other than those described above may also be used.

The health functional food of the present invention can be used as a nutritional supplement, a vitamin, a mineral (electrolyte), a flavor such as a synthetic flavor and a natural flavor, a colorant and an enhancer (cheese, chocolate etc.), a pectic acid and its salt, , Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like.

The present invention also provides a cosmetic composition for preventing hair loss or promoting hair growth comprising Astragaloside IV as an active ingredient.

The ingredients contained in the cosmetic composition of the present invention may contain various ingredients for maintaining the activity of a biocomponent in addition to the Astragaloside IV as an active ingredient such as a preservative, an osmotic agent, a pH adjuster, a buffer, a stabilizer, aluminum hydroxide, aluminum phosphate , Surfactants, liposomes, thickeners, and the like, and customary adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavoring agents, and carriers, and the like, It is not limited.

The cosmetic composition of the present invention can be prepared into any formulation conventionally produced in the art and can be formulated into, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, However, the present invention is not limited thereto. More particularly, the present invention relates to a cosmetic lotion composition comprising a lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray hair conditioner, a hair tonic, Clean skin, hair, hair massages, hair liquids, hair sprays, hair mousse, treatments, non-aerosol mousse, non-aerosol spray, aerosol mousse, aerosol spray, permade, decolorant, shampoo, rinse, shampoo and conditioner A bar or tablet suitable for, a bar of soap, a soap tablet, an aqueous dispersion, a powder and an oil.

When the formulation of the present invention is a paste, a cream or a gel, an animal oil, vegetable oil, wax, paraffin, starch, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar, etc. may be used.

When the formulation of the present invention is a surfactant-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether Alkylamido betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.

Best Mode for Carrying Out the Invention Hereinafter, preferred examples and formulation examples are shown to facilitate understanding of the present invention. However, the following examples and preparative examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples or preparation examples.

Example  1. Identification of induction of hair growth in mice

Animal experiments were conducted with mice to confirm the effect of inducing hair growth in mice by treatment with Astragaloside IV (Sigma, St. Louis, Mo., USA). Seven-week-old pink hairless C57BL / 6 mice (18-20 g) and normal mice were obtained from a laboratory animal center (Osan, Korea) with a hairy root in telogen phase. The animals were maintained at a constant temperature (23 ° C), humidity (55%) and 12 hours of light / dark cycle without limitation. All experiments were carried out in accordance with the Guidelines for the Protection and Use of Laboratory Animals (Ministry of Health and Welfare, NIH publication # 78-23, 1996). 1 μM and 100 μM Astragaloside IV or methanol was applied to the back of the mice (n = 7) locally with hair loss once a day. This process was performed for 5 days / for 15 days and hair regrowth was observed in the dorsal skin of the mice.

The results are shown in Fig.

As shown in Figure 1, treatment with Astragaloside IV induced dose-dependent hair regrowth in C57BL / 6 mice with natural hair loss. On the other hand, mice that did not treat Astragaloside IV remained gray in their natural regression state. The topical application of Astragaloside IV induced hair growth at both 1 and 100 μM doses and was found to exhibit near normal hair restorative capacity in mice treated with 100 μM. In addition, skin color changes, which signify inhibition of the deteriorator and entry into the growing phase, were confirmed by Astragaloside IV treatment.

Example  2. Histological analysis of hair follicles

The mice maintained as in Example 1 were sacrificed after 15 days, and the skin of the mice and the like was removed and fixed with 4% formaldehyde until use, or kept frozen. The skin of the dorsal area fixed with formaldehyde for 24 hours was transferred to PBS (phosphate-buffered saline). Fixed skin was hydrated with ethanol and PBS. Paraffin-fixed sections were cut to a thickness of 4 μM and H & E (Hematoxylin and eosin) staining was performed and hair regrowth was observed. Digital images were obtained using Leica Microsystems software (Leica Microsystems Inc., IL, USA) with Leica Application Suite (LAS) and observed at 100, 200 and 400 magnifications.

The results are shown in Fig.

FIG. 2 shows the hair follicles of a retractor with natural hair loss-induced hair follicle malnutrition along with a broken hair shaft and the result of staining tissue treated with Astragaloside IV. In the experimental group with natural hair loss, no hair was found to penetrate the skin surface, and hair follicles were not found. However, in the experimental group treated with Astragaloside IV, the shape of the hair follicle and the hair and the hair which penetrated the skin surface in the hair follicle were confirmed. As a result, it was confirmed that treatment with Astragaloside IV not only restored tapering of the hairline length but also restored damaged hair. Reversed miniaturized hair follicles showed fewer eosinophils and follicular fibers with worn-out hair follicles.

Example  3. Inhibition of cell death in hair follicles and Caspase -3 reduction

The paraffin slices cut to 4 μM thickness were heated in 10 mM citrate buffer for antigen blocking. For the reduction of endogenous peroxidase, slides were treated with 3% H ₂ O ₂ for 30 minutes and treated with normal goat serum to minimize nonspecific binding. TUNEL and anti-mouse caspase-3 3 IgG (BD Pharmingen, San Jose, Calif., USA) were placed on a slide and placed at 4 ° C for one day. Biotinylated anti-rabbit antibody ) (BD Pharmingen) were treated for 1 hour. After one hour, staining was performed using avidin / biotinylated enzyme complex (ABC) kit (Vector Laboratories, Burlingame, Calif.), And 3,3-diaminobenzidine (DAB; Dako, Glostrup, Denmark). Digital images were acquired using a Leica Application Suite (LAS) microscope software (Leica Microsystems Inc., IL, USA) and magnified 100 times.

The results are shown in Fig. 3 and Fig.

As shown in Fig. 3, the apoptotic pattern of hair regrowth hair follicles of hairless mice was confirmed as TUNEL-positive cells with minimized hair follicles. In the skin of mice treated with Astragaloside IV, a small number of TUNEL-positive cells were found in the HF matrix. Also, as shown in Fig. 4, caspase-3 positive cells were observed in the hair follicles of the hair loss area, and it was confirmed that the treatment with Astragaloside IV significantly reduced caspase-3 positive cells as well as recovery of the hair cells. This confirms that treatment with Astragaloside IV can significantly reduce caspase-3 positive cells as well as recovery of the moraine at the hair loss site.

Example  4. Apoptosis-related protein expression changes

In order to confirm the molecular mechanism of inhibition of regrowth by astragaloside IV treatment, the expression of apoptosis-associated protein was confirmed by Western blot. The whole tissue protein fraction (100 mg, n = 7 / group) of skin tissue was incubated with 2 mL T-PER tissue protein extraction reagent (Pierce, USA) containing a protease inhibitor cocktail (Roche, Indianapolis, Ind. Rockford, IL, USA). The nuclear and cytoplasmic protein fractions (100 mg, n = 7 / group) of skin tissue were suspended in cytoplasmic buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, (20 mM HEPES [pH (1)) containing protease inhibitor cocktail, which was obtained by homogenization in 0.15% Nonidet P-40, 50 mM β-glycerophosphate, 10 mM NaF, 5 mM Na ₃ VO ₄ 7.9], 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.50% Nonidet P-40, 50 mM β-glycerophosphate, 10 mM NaF, 5 mM Na ₃ VO ₄ ) pellet). The resulting homogenate suspension was centrifuged at 12,000 xg for 30 minutes at 4 DEG C, and each supernatant was labeled as whole-tissue, cytoplasm and nuclear protein. c-fos, c-Jun, extracellular signal-regulated kinase (ERK), phosphorylated-ERK (c-fos, c-Jun, (SAPK / JNK), p-SAPK / JNK, p38, p-p38, caspase-3, -8, -9, p53 and Bax were analyzed by Western blotting using the obtained protein fractions. The nuclear protein fraction was used to analyze the activation of NF-κB, and the cytoplasmic protein fraction was used to analyze κB-α and p-IκB-α levels. 30 단백질 protein was electrophoresed on 10% SDS-PAGE gel and transferred to PVDF membrane (Bio-Rad, Hercules, CA, USA). Cells were cultured in the presence of each primary antibody (1: 1000 dilution in 3% BSA (Bovine serum albumin; Cell signaling, USA) and incubated with anti-rabbit alkaline phosphatase -conjugated secondary antibody (1: 2000 dilution in 3% BSA (Bovine serum albumin); Santa Cruz, CA, USA) was used to detect the target protein. After incubation at room temperature for 2 hours, bound antibodies were visually identified by ECL (enhanced chemiluminescence) detection reagent (Amersham Pharmacia, Piscataway, NJ, USA). The relative band density was calculated using a computerized density meter ) System.

The results are shown in Figs. 5 to 9.

As shown in FIG. 5, the expression of caspase-3, -8 and -9, which are apoptotic factors, was decreased by treatment with 1 and 100 μM Astragaloside IV, but decreased in hairless mouse without Astragaloside IV treatment It was not. In addition, Astragaloside IV treatment of mice with hair degradation by cell death showed that Bax and p53 levels were significantly reduced. These results indicate that astragaloside IV has an anti-apoptotic effect.

6 and 7, expression of NF-κB, phosphorylated p-IκB-α and expression of i-Nos and Cox-2 in mouse skin treated with Astragaloside IV were compared with hair loss mice Respectively. These results indicate that treatment of Astragaloside IV blocks NF-κB migration to the nucleus and blocks phosphorylation of IκB-α.

As shown in FIG. 8, it was confirmed whether astragaloside IV inhibited phosphorylation of three MAP kinases. As a result, it was confirmed that ERK, SAPK / JNK and p38 phosphorylation were inhibited by treatment with Astragaloside IV Respectively. Also, as shown in Fig. 9, the reduction of the three MAP kinases was found to be dose dependent, with low levels of c-fos and c-Jun.

Example  5. Regulation of cytokine production

Protein levels of cytokines known to regulate hair growth and regression were assessed using whole-tissue lysates of dorsal skin tissue. Protein assay reagents (Bio-Rad, Hercules, Calif., USA) were used for quantitative analysis of protein concentrations under the same conditions. Tissue cytokine concentrations were determined using mouse TNF-α IL-1β, IFN-y ELISA kit (BD Bioscience, San Jose, Calif., USA). Cytokine levels were calculated as pg / mg total protein. Optical density was measured at 450 nm using an enzyme-linked immunosorbent assay (ELISA) reader (Molecular Devices, Downingtown, Pa.).

The results are shown in Fig.

As shown in FIG. 10, it was confirmed that TNF-α IL-1β, -4 and -6 were increased in the hair loss group. As a result of treatment with Astragaloside IV in the hair loss group, it was confirmed that IL-1β -4 and -6 were significantly decreased in a dose-dependent manner as compared with the untreated group, and that TNF-α was also decreased by astragaloside IV treatment.

All statistical analyzes used in the present invention were determined by ANOVA and nonparametric tests, and p <0.05 was considered statistically significant in all analyzes.

Formulation example  1. Manufacture of medicines

1.1 Sanje  Produce

Astragaloside IV 100 mg

Lactose 100mg

10 mg

The above components are mixed and filled in airtight bags to prepare powders.

1.2 Preparation of tablets

Astragaloside IV 100 mg

Corn starch 100 mg

Lactose 100mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

1.3 Preparation of capsules

Astragaloside IV 100 mg

Corn starch 100 mg

Lactose 100mg

Magnesium stearate 2 mg

The above components are mixed according to a conventional capsule preparation method and filled into gelatin capsules to prepare tablets.

1.4 Manufacture of Injection

Astragaloside IV 100 mg

Sterile sterilized water for injection

pH adjuster

(2 ml) per 1 ampoule in accordance with the usual injection method.

1.5 Liquid  Produce

Astragaloside IV 100 mg

Sugar 20g

20g per isomer

Lemon incense quantity

Purified water was added to make a total of 1,00 ml. The above components are mixed according to a usual method for producing a liquid agent, and then filled in a brown bottle and sterilized to prepare a liquid agent.

Formulation example  2. Manufacture of health functional foods

Astragaloside IV 100 mg

Vitamin mixture quantity

70 [mu] g of vitamin A acetate

Vitamin E 1.0 mg

0.13 mg vitamin B1

0.15 mg of vitamin B2

0.5 mg vitamin B6

0.2 [mu] g vitamin B12

10 mg vitamin C

Biotin 10 μg

Nicotinic acid amide 1.7 mg

50 ㎍ of folic acid

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

15 mg of potassium phosphate monobasic

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

100 mg of calcium carbonate

24.8 mg of magnesium chloride

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a component suitable for a health functional food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above components may be mixed And then used in the manufacture of a health functional food composition (for example, a nutritious candy, etc.) by a conventional method.

Formulation example  3. Preparation of Health Functional Drink

Astragaloside IV 100 mg

Citric acid 1000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water was added to a total of 900 ml

The above components were mixed according to a conventional health functional beverage manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the resulting solution was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, It is used in the manufacture of the health functional beverage composition of the invention.

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the compounding ratio may be arbitrarily varied depending on the regional and national preferences such as the demand level, the demanding country, and the intended use.

Formulation example  4. Manufacture of cosmetics

Astragaloside IV 0.5 wt%

Glycerin 3.0 mg wt%

Hydrogenated lecithin 1.0 mg wt%

Cetostearyl alcohol 2.0 wt%

Polysorbate 60 1.5 wt%

Antioxidant 0.3 wt%

Antiseptic

Purified water quantity

Claims (7)

A pharmaceutical composition for preventing hair loss or promoting hair growth comprising Astragaloside IV as an active ingredient. The pharmaceutical composition according to claim 1, wherein the astragaloside IV promotes hair growth. The pharmaceutical composition according to claim 1, wherein the Astragaloside IV inhibits apoptosis in hair follicles. The method of claim 1, wherein the astragaloside IV reduces the production of at least one cytokine selected from the group consisting of TNF- ?, IL-1 ?, IL-4 and IL? A pharmaceutical composition. The pharmaceutical composition according to any one of claims 1 to 4, wherein the composition has a formulation selected from the group consisting of a liquid preparation for external use, cream, ointment, paste, aerosol, gel and lotion. Astragaloside IV (Astragaloside IV) as an active ingredient to prevent hair loss or promote the growth of health functional food. A cosmetic composition for preventing hair loss or promoting hair growth comprising Astragaloside IV as an active ingredient.

Images